The Board of Directors of the Company comprises of Eight members who have vast experience in the fields of Science, Technology and Management.

Robert J. Coury was elected to the Board of Directors of Mylan Laboratories in 2002 and currently serves as Vice Chairman. Mr. Coury serves as Mylan's Chief Executive Officer, a position he has held since 2002.

Prior to joining Mylan, Mr. Coury was the principal of Coury Consulting L.P., Pittsburgh, PA, and a corporate strategy advisory firm he formed in 1989. Among his accomplishments, Mr. Coury led the $181 million sale/business combination of Crown Communications to Castle Tower, Houston, Texas. Following the sale, Mr. Coury served on the board of the company's largest subsidiary, which was responsible for its United States operations. Later, he was instrumental in the company's $182 million initial public offering and listing on NASDAQ. Today, Crown Castle International Corp. trades on the New York Stock Exchange under the symbol "CCI."

In addition to his business commitments, Mr. Coury is an active participant in civic activities, especially those focusing on the promotion of economic development. Most recently, Mr. Coury assisted community leaders in the successful effort to secure a minor league professional baseball team for a newly constructed stadium in Washington County, PA.

Mr. Coury received a bachelor of science in industrial engineering from the University of Pittsburgh in 1984.

Mr. N. Prasad
Vice Chairman

Mr. N. Prasad has Masters in Science and Business Administration. With a rich experience of over 20 years in the pharmaceutical industry, Mr. Prasad is the driving force behind the successful implementation of M&A strategy at Matrix and has proven his skills in terms of selection, integration and turning around the merged entities.Under the leadership of Mr. Prasad, Matrix has emerged as one of the major players in the Indian pharma industry within four years of the change of its management in May 2000 and laid a strong emphasis on Intellectual Property (IP). He was previously the Managing Director & CEO of Vorin Laboratories.

Mr. Srinivasan is an Engineering graduate with Masters in Management from IRMA Anand. He is also a member of the Institute of Cost and Works Accountants of India.

Mr. Srinivasan has handled various assignments spanning through a number of functional areas such as Finance, Sales & Marketing, Business Development and Strategic Planning, during his 20 years industrial experience.

During his 15 years tenure with Matrix Laboratories Limited, he has made significant contribution in expanding the Company's business in the areas of Active Pharmaceutical Ingredients (API), Anti-retrovirals (ARV) and Finished Dosage Forms (FDF), through both organic growth as well as through Mergers & Acquisitions.

Mr. Rajiv Malik
Director

Mr. Rajiv Malik brings with him over 24 years of rich experiences in generic pharmaceutical industry. He serves as Executive Vice President and Head of Global Technical Operations of Mylan Inc., before which he was CEO of Matrix. Prior to joining Matrix, Mr. Malik was associated with Sandoz, the global generics arm of Novaritis, as its Head of Global Development & Registration, based at Vienna, Austria.

At Sandoz, Mr. Malik was responsible for its worldwide product flow, global project management, Development strategy for R&D, besides overall planning, strategizing, budgeting & resource allocation and necessary interaction with the customers. He was also responsible for overseeing the network of eight development centers of Sandoz worldwide.

Mr. Malik had a 20 year stint with Ranbaxy Laboratories Limited before joining Sandoz in 2003, during which he has served as the Head of Pharma Research & Global Regulatory Affairs. At Ranbaxy, Mr. Malik’s responsibilities include development and registration of generics for US, Europe, Australia, New Zealand, Latin America and China.

Mr. Malik has Masters in Pharmacy from Punjab University. With about 60 formulation process patents and 10 publications in pharmaceutical journals to his credit, Mr. Malik has a thorough knowledge of global regulatory matters in the pharma industry. He is a member of the Regulatory Affairs Professional Society, USA.

Mr. Ramakrishna is a Chartered and Cost Accountant having more than 20 years of rich experience in the areas of Project Finance, Corporate Finance, Strategic Planning, General Management and Corporate affairs. He advises the company on all the strategic issues in the capacity of Corporate Advisor.

Mr. Subrahmanian is a graduate in Economics and has a Management Degree from the UK with 46 years of industrial experience in commercial and general management.

Prof. Indiresan is a fellow of the Indian National Academy of Engineering and a distinguished fellow of both the Institute of Electronics and Telecommunication Engineers and the Society of Electronic Engineers. He has 40 years of teaching experience and was awarded the Padma Bhushan in 2000.

Dr. Fred E. Cohen is a Professor, University of California, San Francisco, Departments of Cellular & Molecular Pharmacology, Medicine, and Biochemistry & Biophysics. He was a fellow of Postdoctoral Research in Department of Pharmaceutical Chemistry at University of California.

Dr. Cohen has rich experience in global pharmaceutical industry as a member of Scientific Advisory Boards for several companies. He was also a consultant to Eli Lilly & Co., Indianapolis, IN.

Dr. Cohen has filed several patents and has several research publications to his credit. He has received various awards and honors for his contribution in academics and public service.